VC Fund Dossiers

3VC is the disciplined European operator you want when the market gets frothy. While other funds were throwing money at inflated rounds in 2021, they stayed selective with their 3-4 deals per year strategy. This 'quality over quantity' approach paid off with 3 unicorns from just 12 Fund I companies - that's a 25% unicorn rate that would make Sequoia jealous. The team genuinely gets product-market fit (Eva's IoT background shows) and isn't afraid to get their hands dirty - they literally structured Gamee's acquisition by Animoca Brands during tough times. The downside? They're picky as hell and take forever to decide, plus their DACH/CEE focus means they might miss broader European trends.

APEX Ventures is the rare European deep tech fund that actually understands what they're investing in - probably because their partners have real operational experience rather than just finance backgrounds. Andreas Riegler built and sold companies before becoming a VC, Wolfgang Neubert has deep technical expertise in photonics and quantum, and Gordon Euller is a practicing radiologist who worked at McKinsey. This translates into genuine value-add for founders wrestling with complex IP strategies and brutal commercialization timelines. The €80M Amadeus APEX Technology Fund partnership gives them serious firepower, and their portfolio companies consistently praise their hands-on support and network introductions. However, they're primarily focused on DACH region deals, so if you're not in Germany/Austria/Switzerland, you might be swimming upstream. Also, while they talk a good game about being 'founder-friendly,' deep tech investors by nature tend to want more control given the long development cycles and capital intensity.

Here's the thing about b2venture - they're not your typical fund throwing money around hoping something sticks. Their 350+ angel investor community isn't just marketing fluff - it's their actual superpower, and founders consistently rave about the network effects. SumUp's founders literally said 'we'd always work with them again' and praised their ability to mobilize angels for later rounds. Track record speaks for itself: at least one unicorn per fund generation, 11 IPOs, 30+ trade sales. But here's what they won't tell you in their deck meetings - they're explicitly hunting for companies that can have 'very large exits' and short-term wins 'rarely move the needle' for them. So if you're building a lifestyle business or looking for a quick flip, look elsewhere. They want category-defining companies and have the patience to get there.

It's dubbed this approach 'high conviction investing'. 'Our philosophy is that we only succeed if the team succeeds; we're in it together,' she adds. Blossom walks the walk on founder support — they genuinely limit themselves to 5-6 deals per year so they can be ridiculously helpful. Unlike a typical lead Series A investor, Blossom generally doesn't take a board seat — it sits on boards for just two of its eight portfolio companies. Instead, Blossom builds dashboards with its portfolio companies, so that the team has live access to tracking metrics and data on the startups. They've cracked the code on being a true partner without being overbearing. The team has serious technical chops (Imran) plus strong US connections (Alex from IVP), and Ophelia's reputation for responsiveness is legendary. Their track record speaks volumes — Blossom Capital has a portfolio of 44 companies, including 6 unicorns. They're expensive (large Series A checks) but if you want a VC who genuinely rolls up sleeves and opens doors globally, they deliver.

BlueYard is what happens when former Earlybird partners decide to bet the farm on civilization ending or reaching utopia - and somehow nail the timing on both fronts. Their first fund's 76% gross IRR and 3.4x DPI speaks for itself, driven by getting into crypto in 2016, AI chips in 2018, and defense tech in 2023 when everyone else thought these spaces were radioactive. They're genuinely 'fluent in weirdness and volatility' - this isn't marketing speak. If you've been told you're 'too early, not big enough, or not in their category,' they literally want you to call them. The partners actually do deep technical diligence and aren't afraid to lead rounds in spaces that make other VCs uncomfortable. Fair warning: they're genuinely contrarian, so if you're building something obvious or looking for validation, this isn't your fund.

This is classic old-school UK venture capital - the kind that's been around since 1999 and has the battle scars to prove it. They've delivered solid returns with 14 profitable exits since 2015 averaging 4.7x, including some standout wins like R2C Online at 12.6x and Accutronics at 9.1x. What's refreshing is they actually take board seats and get their hands dirty - each partner has direct portfolio responsibility and they're not afraid to help with hiring, customer introductions, and financial strategy. With £130m under management, they're mid-sized but experienced. The downside? They're a small team (2-10 employees) which means limited bandwidth, and their heavy life sciences focus means if you're not in healthcare/biotech, you're probably not their cup of tea. They seem genuinely committed to long-term value creation rather than quick flips, which is either exactly what you want or frustratingly slow depending on your timeline.